What is Candid Therapeutics worth?
$657.0Mlast known valuation
Candid Therapeutics last raised $370.0M in its Early Stage VC (Series B) (Aug 2024).
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Candid Therapeutics
Create free account
No card required
Funding history
1 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Aug 2024 | Early Stage VC (Series B) | $370.0M | ▮ | ▮ |
How Candid Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Candid Therapeutics, we compose those signals into the PA Mark — a weighted composite of 1 recent pricing inputs, decayed by age and reset on new rounds. The implied valuation multiplies the mark by shares outstanding. Full methodology →
Frequently asked
- What is Candid Therapeutics worth?
- Candid Therapeutics's implied valuation is $657.0M, based on the PA Mark composite price of about $4 per share as of Sep 2026.
- How much has Candid Therapeutics raised?
- Candid Therapeutics has raised $445.0M in total funding across 1 recorded rounds.
- When did Candid Therapeutics last raise?
- Candid Therapeutics last raised in Aug 2024 (Early Stage VC (Series B)), raising $370.0M.